Plasmablastic lymphoma associated to Crohn's disease and hepatitis C virus chronic infection

被引:9
作者
Plaza, Rocio [1 ]
Ponferrada, Angel [1 ]
Benito, Dulce M. [2 ]
Arevalo, Noelia [3 ]
Angeles Foncillas, Maria [4 ]
Luisa de Fuenmayor, Maria [5 ]
Aldeguer, Mercedes [1 ]
机构
[1] Hosp Infanta Leonor, Dept Gastroenterol, Madrid, Spain
[2] Hosp Infanta Leonor, Dept Pathol, Madrid, Spain
[3] Hosp Infanta Leonor, Dept Radiol, Madrid, Spain
[4] Hosp Infanta Leonor, Dept Hematol, Madrid, Spain
[5] Hosp Infanta Leonor, Dept Surg, Madrid, Spain
关键词
Plasmablastic lymphoma; Immunomodulators; Anti-TNF; Crohn's disease; Hepatitis C virus; INFLAMMATORY-BOWEL-DISEASE; NON-HODGKIN-LYMPHOMA; T-CELL LYMPHOMA; IMMUNOSUPPRESSIVE THERAPY; PATIENT; RISK; AZATHIOPRINE; EPIDEMIOLOGY; INFLIXIMAB;
D O I
10.1016/j.crohns.2011.07.002
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Plasmablastic lymphoma is a very rare and recently-described subtype of diffuse large B-cell lymphoma. It has a poor prognosis despite intensive chemotherapy treatment. A 57-year old woman with perianal Crohn's disease receiving azathioprine and infliximab developed this type of lymphoma after a short period of time on the treatment. She also had a hepatitis C virus chronic infection which had not been diagnosed or treated before. There is no solid scientific evidence that either immunomodulators or anti-TNF drugs have a definitive role in the appearance of malignancies, and therefore there are no clear recommendations to limit their use. In these patients, there are some other factors we have to take into account, like the inflammatory bowel disease in itself and its behaviour over time, or the comorbidities of the patient, with special attention to virus infections. In this case report, we will analyse the role of these factors in the development of lymphoproliferative disorders and the recommendations given by experts to avoid their appearance. (C) 2011 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:628 / 632
页数:5
相关论文
共 22 条
[1]   Risk of Cancer in Inflammatory Bowel Disease Treated With Azathioprine: A UK Population-Based Case-Control Study [J].
Armstrong, Richard G. ;
West, Joe ;
Card, Timothy R. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 (07) :1604-1609
[2]   Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study [J].
Beaugerie, Laurent ;
Brousse, Nicole ;
Bouvier, Anne Marie ;
Colombel, Jean Frederic ;
Lemann, Marc ;
Cosnes, Jacques ;
Hebuterne, Xavier ;
Cortot, Antoine ;
Bouhnik, Yoram ;
Gendre, Jean Pierre ;
Simon, Tabassome ;
Maynadie, Marc ;
Hermine, Olivier ;
Faivre, Jean ;
Carrat, Fabrice .
LANCET, 2009, 374 (9701) :1617-1625
[3]   Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease [J].
Bewtra, Meenakshi ;
Lewis, James D. .
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2010, 6 (04) :621-631
[4]   Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine [J].
Dayharsh, GA ;
Loftus, EV ;
Sandborn, WJ ;
Tremaine, WJ ;
Zinsmeister, AR ;
Witzig, TE ;
Macon, WR ;
Burgart, LJ .
GASTROENTEROLOGY, 2002, 122 (01) :72-77
[5]   Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the international lymphoma epidemiology consortium [J].
De Sanjose, Silvia ;
Benavente, Yolanda ;
Vajdic, Claire M. ;
Engels, Eric A. ;
Morton, Lindsay M. ;
Bracci, Paige M. ;
Spinelli, John J. ;
Zheng, Tongzhang ;
Zhang, Yawei ;
Franceschi, Silvia ;
Talamini, Renato ;
Holly, Elizabeth A. ;
Grulich, Andrew E. ;
Cerhan, James R. ;
Hartge, Patricia ;
Cozen, Wendy ;
Boffetta, Paolo ;
Brennan, Paul ;
Maynadie, Marc ;
Cocco, Pierluigi ;
Bosch, Ramon ;
Foretova, Lenka ;
Staines, Anthony ;
Becker, Nikolaus ;
Nieters, Alexandra .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2008, 6 (04) :451-458
[6]   Non-Hodgkin's lymphoma and other nonhepatic malignancies in Swedish patients with hepatitis C virus infection [J].
Duberg, AS ;
Nordström, M ;
Törner, A ;
Reichard, O ;
Strauss, R ;
Janzon, R ;
Bäck, E ;
Ekdahl, K .
HEPATOLOGY, 2005, 41 (03) :652-659
[7]   Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease [J].
Gisbert, J. P. ;
Chaparro, M. ;
Esteve, M. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 33 (06) :619-633
[8]   Plasmablastic Lymphoma of the Cecum: Report of a Case With Cytologic Findings [J].
Hatanaka, Kazuhito ;
Nakamura, Naoya ;
Kishimoto, Koji ;
Sugino, Keishi ;
Uekusa, Toshimasa .
DIAGNOSTIC CYTOPATHOLOGY, 2011, 39 (04) :297-300
[9]   Lymphoma risk in inflammatory bowel disease: Is it the disease or its treatment? [J].
Jones, Jennifer L. ;
Loftus, Edward V., Jr. .
INFLAMMATORY BOWEL DISEASES, 2007, 13 (10) :1299-1307
[10]   Safety of infliximab and other Crohn's disease therapies - Treat registry data with nearly 15,000 patient-years of follow-up [J].
Lichtenstein, Gary R. ;
Cohen, Russell D. ;
Feagan, Brian G. ;
Sandborn, William J. ;
Salzberg, Bruce A. ;
Chen, Donny M. ;
Pritchard, Michelle L. ;
Broussard, Delma L. ;
Diamond, Robert H. .
GASTROENTEROLOGY, 2006, 130 (04) :A71-A71